@article{ref1,
title="US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior",
journal="Journal of comparative effectiveness research",
year="2022",
author="Voelker, Jennifer and Sheehan, John J. and Le, Hoa H. and Toro-Diaz, Hector and Li, Shujun and Joshi, Kruti",
volume="11",
number="5",
pages="319-328",
abstract="BACKGROUND: Esketamine nasal spray plus an oral antidepressant is approved in adults with major depressive disorder with acute suicidal ideation or behavior (MDSI). <br><br>METHODS: A budget impact analysis from a US payer perspective was performed with a hypothetical 1-million-member plan, using pharmacy and medical costs associated with adding esketamine plus an oral antidepressant to usual care. <br><br>RESULTS: Estimated annual total healthcare costs of managing patients with MDSI increased from $32,988,247 without esketamine to $34,161,188 in Year 3 with esketamine (primarily due to medical costs). The per-member-per-month incremental costs were $0.02, $0.06 and $0.10 in Years 1, 2 and 3, respectively. <br><br>CONCLUSION: Incorporation of esketamine results in a modest estimated impact on the annual budget over a 3-year time horizon.<p /><p>Language: en</p>",
language="en",
issn="2042-6305",
doi="10.2217/cer-2021-0226",
url="http://dx.doi.org/10.2217/cer-2021-0226"
}